FIELD: pharmacology.
SUBSTANCE: invention relates to new phenylcycloalkylmethylamine derivatives of structural formula (I), or enantiomers or optically active isomers, or pharmaceutically acceptable salts having affinity for the binding of dopamine (DAT), the carrier of norepinephrine (NET) and the serotonin transporter (SERT). The compounds may find use in treatment and/or prevention of obesity, as well as depression 1. In the structural formula (I)
,
n is 1; SP is a spacer, wherein the said spacer is C4 alkylene; X is O or S; R1 and R2 are independently H, C1-6 alkyl, C1-6 alkoxy, halogen; R3 is C1-6 alkyl; R4 is H or C1-6 alkyl; R5 is C1-6 alkyl; and * represents a carbon atom that can be optically active.
EFFECT: improved composition properties.
12 cl, 1 tbl, 86 ex
Title | Year | Author | Number |
---|---|---|---|
ARGINASE INHIBITORS AND THERAPEUTIC USE THEREOF | 2011 |
|
RU2586219C2 |
CALPAIN MODULATORS AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773288C2 |
SUBSTITUTED BENZENE COMPOUNDS | 2013 |
|
RU2658919C2 |
COMPOUNDS APPLICABLE FOR TREATING AIDS | 2010 |
|
RU2575845C2 |
ANTIFIBROUS PYRIDINONES | 2015 |
|
RU2692485C2 |
NOVEL COMPOUNDS OF CONDENSED IMIDAZOLE POSSESSING OF CB2 RECEPTOR AGONIST PROPERTY | 2002 |
|
RU2312864C2 |
COMPOUNDS SUITABLE FOR CANCER TREATMENT | 2010 |
|
RU2567752C2 |
10H-PHENOTHIAZINE FERROPTOSIS INHIBITORS, THEIR PRODUCTION METHOD AND THEIR USE | 2019 |
|
RU2787366C2 |
MACROHETEROCYCLIC NUCLEOSIDE DERIVATIVES AND ANALOGUES THEREOF, PRODUCTION AND USE | 2017 |
|
RU2731385C1 |
EP4 ANTAGONISTS | 2016 |
|
RU2761341C2 |
Authors
Dates
2018-01-24—Published
2012-12-31—Filed